Castle Biosciences (NASDAQ:CSTL) COO Kristen Oelschlager Sells 12,384 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 12,384 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $34.42, for a total value of $426,257.28. Following the transaction, the chief operating officer owned 72,649 shares of the company’s stock, valued at approximately $2,500,578.58. The trade was a 14.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Castle Biosciences Price Performance

Shares of Castle Biosciences stock opened at $34.08 on Thursday. The firm has a market cap of $1.04 billion, a PE ratio of -51.64 and a beta of 0.98. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The stock has a 50 day moving average of $26.73 and a 200 day moving average of $25.41. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%. On average, research analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CSTL has been the topic of a number of recent analyst reports. Roth Capital started coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price objective on the stock. Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Robert W. Baird set a $36.00 price target on Castle Biosciences in a report on Friday, July 31st. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Zacks Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Hedge Funds Weigh In On Castle Biosciences

Large investors have recently added to or reduced their stakes in the company. Amundi grew its position in shares of Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares during the last quarter. AQR Capital Management LLC grew its stake in Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares in the last quarter. Jones Financial Companies Lllp raised its stake in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Castle Biosciences by 34.7% in the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after buying an additional 8,992 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.